TLSA — Tiziana Life Sciences Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723069 ·
Last close
$1.13
Market Cap
$143.80M
52W High
$2.30
52W Low
$0.76
ADV30
610,628
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 11,495,000 | 4,010,000 | 11,443,000 |
| Dec 2024 | — | — | — | — | 11,284,000 | 3,724,000 | 7,348,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-163,109,000
Inventory
—
Receivables
$4,257,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,132,000 | -18,431,000 | 11,495,000 | 11,443,000 | 52,000 | -12,847,000 |
| Dec 2024 | 0 | -15,794,000 | -11,863,000 | 11,284,000 | 7,348,000 | 3,936,000 | -1,526,000 |
| Dec 2023 | 0 | -17,984,000 | -17,691,000 | 12,184,000 | 6,648,000 | 5,536,000 | -15,698,000 |
| Dec 2022 | 0 | -14,586,000 | -15,397,000 | 26,477,000 | 6,906,000 | 19,571,000 | -19,615,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNA | Atrium Therapeutics, Inc. | $141.29M | $8.26 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $137.10M | $0.95 | — |
| NERV | Minerva Neurosciences, Inc. | $153.75M | $3.22 | — |
| VRXA | Veraxa Biotech AG - Post de-SPAC | $154.13M | $1.09 | — |
| KRRO | Korro Bio, Inc. | $155.80M | $10.58 | — |
News headlines (Yahoo Finance, 1h cache)
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
2026-09-30 12:54 · Yahoo
MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq
2026-09-30 11:14 · Yahoo
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
2026-09-30 11:00 · Yahoo
Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial
2026-09-29 13:53 · Yahoo
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
2026-09-28 13:14 · Yahoo
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
2026-09-28 11:00 · Yahoo
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
2026-09-21 13:28 · Yahoo
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
2026-09-21 11:00 · Yahoo
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
2026-09-17 13:39 · Yahoo
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
2026-09-03 19:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.